Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 3—March 2011

Laboratory-based Surveillance of Extensively Drug-Resistant Tuberculosis, China

Yunfeng Deng, Yan Wang, Junling Wang, Hui Jing, Chunbao Yu, Haiying Wang, Zhimin Liu, Edward A. Graviss, and Xin MaComments to Author 
Author affiliations: Author affiliations: Shandong Provincial Chest Hospital, Jinan, People’s Republic of China (Y. Deng, Y. Wang, J. Wang, H. Jing, C. Yu, H. Wang, Z. Liu, X. Ma); The Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss, X. Ma)

Main Article

Table 2

Second-line drug resistance of 107 MDR Mycobacterium tuberculosis isolates, People’s Republic of China, November 2004–April 2007*

Drugs No. isolates Rate, %
Overall second-line drug resistance 65 60.7
FQ 57 53.3
AMK 19 17.8
CPM 24 22.4
XDR, total 20 18.7
FQ + AMK 4 3.7
FQ + CPM 4 3.7
FQ + AMK + CPM 5 4.7
FQ + AMK + PAS 2 1.9
FQ + CPM + PAS 3 2.8
FQ + AMK + CPM + PAS 2 1.9

*MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin and levofloxacin); AMK, amikacin; CPM, capreomycin; PAS, para-aminosalicylic acid; XDR, extensively drug-resistant.

Main Article

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.